Company intelligence / Profile preview

Graft Polymer

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Graft Polymer is focused on developing and licensing novel drug delivery technologies. Its collaboration with Awakn Life Sciences targets pre-clinical assets for trauma-related mental health disorders with early-stage co-lead candidates. As of the most recent disclosures, no clinical trial readouts have been reported for their drug delivery platform in licensed products.

Therapeutic areas: Psychiatry
Modalities: Polymer-drug conjugate therapySmall molecule
Industry: Biotech

Partnerships

Awakn Life Sciences

Beyond the preview

Go deeper on Graft Polymer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Graft Polymer.

Explore the full profile